IPPRA / Grant Monitor

2026-07-07
← Board

DoW Lupus, Transformative Vision Development Award

HT942526LRPTVDA · Defense Health Agency Contracting Activity - DHACA

biomedical clinical public health Science & Technology R&D

Closes
2026-08-24 · 48 d
Award ceiling
Award floor
Program funding
$500,000
Expected awards
2
Cost sharing
No
Posted
2026-05-05
Instrument
Grant
Characterization · gpt-5.4-mini · 2026-07-07

Supports planning, development, and pilot studies for future lupus interventional research, including phase 0/1 clinical trials, for teams that include at least one lupus consumer advocate.

Funds
applied research
University
direct
social behavioral
minor
engineering
minor
life biomedical
central
computational data
minor

⚑ Must address at least one FY26 LRP Transformative Vision Development Award focus area. · At least one lupus consumer advocate is required on the research team. · Phase 2/3 clinical trials and animal studies are not allowed. · PI may be named on only one application per LRP award mechanism; max four FY26 LRP applications per individual across specified mechanisms.

Unit fits — one characterization, each unit's own rules

IPPRA 58 good portfolio topic: public_health; social/behavioral work is minor; funds applied research; clinical-trial/biomedical core — IPPRA angle is policy/community (capped)
Physical Sciences & Engineering (demo) 55 good technical depth: minor; funds applied research
Tom Love Innovation Hub 30 weak funds applied research; deep-tech content

Description

Summary: This funding mechanism supports planning and development activities and pilot studies that will generate preliminary data and demonstrate feasibility for achieving the aims of a future interventional study. Successful studies may be submitted to a future Lupus Research Program (LRP) Transformative Vision Award (TVA), or equivalent, for funding consideration (See Funding Opportunity Number HT942526LRPTVA for additional information). Research must address at least one of the fiscal year 2026 (FY26) LRP Transformative Vision Development Award (TVDA) focus areas. This funding mechanism allows for phase 0/1 clinical trials, if appropriate. The mechanism does not allow for phase 2/3 clinical trials or animal studies.

Distinctive Features:

• Preliminary data are permitted but not required.

• Applications must include at least one lupus consumer advocate as a member of the research team.

• An individual may be named as Principal Investigator (PI) on only one application per LRP award mechanism (Idea Award, Impact Award, TVDA, TVA), for a maximum of four applications to the FY26 LRP.

Apply

View on Grants.gov → CONTACT: Abigail Strock Contract Specialist <help@eBRAP.org>

Proposal brief

ONE LLM CALL (~1¢) · CACHED · REQUIRES STAFF KEY

Proposal shell · Department of Defense (BAA-style) conventions

ONE LLM CALL (~2-3¢) · CACHED · SCAFFOLDING, NOT GHOSTWRITING